

Title (en)
METHOD AND COMPOSITION FOR TREATING ANGIOGENESIS AND FOR PREVENTING CANCER PROGRESSION AND METASTASIS COMPRISING A PROSTATE SECRETORY PROTEIN (PSP94) FAMILY MEMBER

Title (de)
VERFAHREN UND ZUSAMMENSETZUNG ZUR BEHANDLUNG VON ANGIOGENESE UND ZUR PRÄVENTION DER AUSBREITUNG VON KREBS UND METASTASENBILDUNG ENTHALTEND EIN MITGLIED EINER PROSTATE SECRETORY PROTEIN-FAMILIE (PSP94)

Title (fr)
PROCEDE ET COMPOSITION POUR LE TRAITEMENT DE L'ANGIOGENESE ET POUR LA PREVENTION DE LA PROGRESSION DU CANCER ET DE METASTASES COMPRENANT UN MEMBRE DE LA FAMILLE DES PROTEINES SECRETEES PAR LA PROSTATE (PSP94)

Publication
EP 1765852 A4 20080611 (EN)

Application
EP 05714663 A 20050321

Priority

- CA 2005000430 W 20050321
- US 85735804 A 20040601
- US 94822904 A 20040924
- US 427004 A 20041202
- US 427304 A 20041202

Abstract (en)
[origin: WO2005118623A1] Angiogenesis, the formation of new blood vessels, is an integral part of normal physiological and developmental processes as well as several pathologies, ranging from tumor growth and metastasis to inflammation and ocular disease. Methods and compositions are provided for controlling normal angiogenesis and for treating angiogenesis associated or mediated diseases as well as for preventing cancer progression and metastasis through the use of a prostrate secretory protein (PSP) family member.

IPC 8 full level
A61K 38/10 (2006.01); **A61P 9/00** (2006.01); **A61P 35/00** (2006.01); **C07K 7/06** (2006.01); **C07K 7/08** (2006.01)

CPC (source: EP)
A61K 38/10 (2013.01); **A61P 9/00** (2017.12); **A61P 17/06** (2017.12); **A61P 27/02** (2017.12); **A61P 29/00** (2017.12); **A61P 35/00** (2017.12); **A61P 35/04** (2017.12); **C07K 7/06** (2013.01); **C07K 7/08** (2013.01)

Citation (search report)

- [E] WO 2005033141 A1 20050414 - PROCYON BIOPHARMA INC [CA]
- [X] LAMY SYLVIE ET AL: "Green tea catechins inhibit vascular endothelial growth factor receptor phosphorylation", CANCER RESEARCH, vol. 62, no. 2, 15 January 2002 (2002-01-15), pages 381 - 385, XP002477716, ISSN: 0008-5472
- [X] BÉLIVEAU RICHARD ET AL: "The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects.", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH APR 2002, vol. 8, no. 4, April 2002 (2002-04-01), pages 1242 - 1250, XP002477717, ISSN: 1078-0432
- [X] GINGRAS DENIS ET AL: "Tyrosine phosphorylation of the vascular endothelial-growth-factor receptor-2 (VEGFR-2) is modulated by Rho proteins", BIOCHEMICAL JOURNAL, vol. 348, no. 2, 1 June 2000 (2000-06-01), pages 273 - 280, XP002477718, ISSN: 0264-6021
- [T] LAMY SYLVIE ET AL: "A prostate secretory protein94-derived synthetic peptide PCK3145 inhibits VEGF signalling in endothelial cells: Implication in tumor angiogenesis", INTERNATIONAL JOURNAL OF CANCER, vol. 118, no. 9, May 2006 (2006-05-01), pages 2350 - 2358, XP002477719, ISSN: 0020-7136
- See references of WO 2005118623A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR

Designated extension state (EPC)
AL BA HR LV MK YU

DOCDB simple family (publication)
WO 2005118623 A1 20051215; AU 2005250059 A1 20051215; CA 2567901 A1 20051215; EP 1765852 A1 20070328; EP 1765852 A4 20080611; JP 2008501645 A 20080124

DOCDB simple family (application)
CA 2005000430 W 20050321; AU 2005250059 A 20050321; CA 2567901 A 20050321; EP 05714663 A 20050321; JP 2007513628 A 20050321